Skip to main content
. 2018 Mar 23;9(36):24260–24271. doi: 10.18632/oncotarget.24916

Figure 7. Effect of HX-1171 on blood glucose levels in the STZ-induced diabetic mouse model.

Figure 7

(A) Blood glucose levels and (B) serum insulin levels in untreated, STZ (200 mg/kg, i.p.) and HX-1171 (125 mg/kg, p.o.)-co-treated mice 1 day after STZ treatment. (C) Blood glucose levels in untreated, STZ, HX-1171-co-treated and HX-1171-post-treated (p.o. one day after STZ injection) mice at the indicated days. (D) The average level of blood glucose in mice at the indicated days. Blood glucose levels were measured using an Accu-Chek glucometer, and serum insulin levels were measured by ELISA. ●: Control (n = 5), ■: STZ (n = 6), ▲: HX-1171-co-treat (n = 6), ♦: HX-1171-post-treat (n = 6). Data are presented as mean ± SD. **P < 0.005, ***P < 0.001 compared to the control group, ##P < 0.005, ###P < 0.001 compared to the STZ group.